CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Roma, Italy and 105 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 2
Terni, Italy and 47 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Rome, Italy and 130 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Rome, Italy and 80 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Roma, Italy and 145 other locations
study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...
Phase 1, Phase 2
Roma, Italy and 74 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Roma, Italy and 231 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Roma, Italy and 196 other locations
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...
Phase 3
Roma, Lazio, Italy and 47 other locations
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...
Phase 3
Roma, Italy and 178 other locations
Clinical trials
Research sites
Resources
Legal